Recent years have witnessed notable progress in tailoring treatments for solid tumors using biomarkers. Nevertheless, identifying specific biomarkers for Low-Grade Non-Hodgkin Lymphomas remains a challenge. In the case of CLL, certain indicators such as TP53 mutations, 17p deletion, and IGHV mutational status have been associated with disease outlook and treatment efficacy. The abnormal regulation of the B-cell receptor (BCR) signaling pathway and molecular targets including CD20, Bruton's tyrosine kinase (BTK), CXCR4, CD32, and CD5 are essential in B-CLL pathogenesis. For WM, mutations in MYD88 and CXCR4 genes are central to disease development and therapeutic targeting. Furthermore, genetic changes like the t(14;18) translocation in follicular lymphomas, the t(11;14) translocation and cyclin D1 overexpression in mantle cell lymphomas, and the BRAF V600E mutation in hairy cell leukemia require additional study for personalized therapies, particularly for second-line treatments and potential first-line individualized approaches based on predictive markers. The critical function of microRNAs (miRNAs) and epigenetic modifications in the onset and advancement of these diseases is also gaining recognition, as these regulatory mechanisms influence gene expression and disease pathogenesis.

This research topic seeks to pinpoint actionable targets for tailored therapies in Low-Grade Non-Hodgkin Lymphomas, with an emphasis on second-line treatments and investigating the potential for personalized initial treatments based on predictive markers. The study will examine the impacts of miRNAs and epigenetic alterations, as well as the tumor microenvironment, on treatment responses and disease progression. By exploring these areas, the research aims to uncover innovative therapeutic targets and strategies to enhance patient outcomes in Low-Grade Non-Hodgkin Lymphomas.

To gather further insights in the identification of new molecular targets for personalized treatment in Low-Grade Non-Hodgkin Lymphomas, we welcome articles addressing, but not limited to, the following themes:
- The role of the tumor microenvironment in disease development and treatment response
- Mechanisms of immune evasion and novel immunotherapeutic targets
- Personalized immunotherapy approaches and their potential impact
- Interactions between intracellular molecular pathways and the microenvironment
- Development of new combination treatment strategies based on molecular and microenvironmental interactions
- The impact of miRNAs and epigenetic alterations on gene expression and disease pathogenesis
- Exploration of predictive markers for personalized first-line treatments.

Impact

Frontiers in Hematology

Blood Cancer